Current Funding
National Institutes of Health CA269866-02
Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma
National Institutes of Health DA057787-02
Identification of allosteric molecules for DOR-KOR heteromer-mediated peripheral analgesia
National Institutes of Health AI180213-01A1
Preclinical Testing of Potential Next-generation Antischistosomal Compounds
Cancer Prevention & Research Institute of Texas, RP210208
Center for Innovative Drug Discovery: Expansion of a Highly Productive Shared Cancer Drug Discovery Resource for Texas
Department of Defense W81XWH-22-1-0070
Development of Antiviral Therapies Against Nipah and Hendra Viruses
Completed Funding
Cancer Prevention & Research Institute of Texas, RP200058
Enhancing Cytarabine Response Through SAMHD1 Inhibition
San Antonio Partnership for Precision Therapeutics
Development of antiviral therapies against Nipah and Hendra viruses
San Antonio Partnership for Precision Therapeutics
Blocking SARS-CoV-2 Evasion from Innate Antiviral Defenses
San Antonio Partnership for Precision Therapeutics
Role of FURIN in COVID-19 and Underlying Molecular and Immunological Mechanisms
San Antonio Partnership for Precision Therapeutics
Mechanism-Based Targeting of an RNA Processing Pathway
NIH 5UL1TR002645 (P.I. Core Facility)
Institution for the Integration of Medicine and Science: A Partnership to Improve Health CTSA Optional Core Facility Grant
Department of Defense CDMRP, PR171296
Protein Kinase C Epsilon Inhibitors to Treat Pain. Collaboration with UT Austin and UC San Francisco
Cancer Prevention & Research Institute of Texas, RP160844
Center for Innovative Drug Discovery: Enhancement of a Shared Cancer Resource for South Texas. Collaboration with UT Health San Antonio.
Greehey Children’s Cancer Center Pilot Award, SAT0002969
Validation and Development of PROTAC’s for Pediatric Cancers
National Institutes of Health R01 AI119554
Development of novel chemical series of Candida albicans biofilm inhibitors. Collaboration with Jose Lopez Ribot (UTSA).
National Institutes of Health R01 AI115691
Structure-guided redesign of an antischistosomal drug. Collaboration with UT Health San Antonio and Texas BioMed.
NIH U54 Mays Cancer Center Pilot Program Grant
Treatments for Pediatric Liver Tumors
San Antonio Medical Foundation Grant
A High-Throughput, High-Content Screen of iPSC-Derived Dopaminergic Neurons for Neuroprotective Compounds
IIMS/CTSA (NIH) pilot award, NIH 5UL1TR002645
“Development of novel FAAH Inhibitors for the Treatment of Schizophrenia”. Collaboration with UT Health San Antonio
Cancer Prevention & Research Institute of Texas, DP150055
Druggable Targets that Regulate the Antitumor Activity of ER-beta. Collaboration with UT Health San Antonio.
Department of the Army, Medical Research, PR141776
Discovery of Novel N-Nicotinamide Methyltransferase Inhibitors to Combat Obesity-Linked Osteoarthritis and Metabolic Disease among Veterans and Beneficiaries. Collaboration with UTMB Galveston.
IIMS/CTSA (NIH) pilot award. NIH 5UL1TR002645
Discovery of novel inhibitors of oncoprotein EYA2 in breast and ovarian cancers. Collaboration with UT Health San Antonio.